Company Overview of F2G Ltd.
F2G Ltd engages in the discovery and development of drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. It involves in the robotic-based whole cell screening and HTS of MycoBank generated targets for improved treatments for invasive fungal infections. The company’s MycoBank is a platform technology for the identification of genes in aspergillus fumigatus. It also provides scientific services, such as research services, including offer a range of techniques for evaluating anti-infectives, which include MIC testing to CLSI, high throughput screens, bio-informatics, and analytical methods. The company was formerly known as Functional Fungal Genomics...
Manchester, M30 0BH
Founded in 1998
44 1617 851 270
44 1617 851 273
Key Executives for F2G Ltd.
Chief Executive Officer and Executive Director
Chief Scientific and Development Officer
Non-Executive Chairman and Member of Management Board
Compensation as of Fiscal Year 2013.
F2G Ltd. Key Developments
F2G Ltd. and University of Manchester Announce a New €6.1 Million Project to Develop New Antifungal Agents
Jun 26 13
F2G Ltd. and University of Manchester announced the commencement of a EUR 6.1 million EU-funded project to discover and develop novel antifungal drugs to treat serious, life-threatening fungal infections. The NOFUN project is a collaborative project under the 7th Framework Program of the European Commission which brings together five partners to accelerate the development of a number of F2G’s broad spectrum antifungal agents. About two million people die each year because of fungal infection and resistance is rapidly emerging to the most common drugs used to treat these diseases. This project aims to develop novel agents with completely new ways of acting in order to combat the increasing tide of drug resistant fungal infections. NOFUN will use F2G’s discovery assets and the University’s fungal genomics platforms in addition to the drug development and characterisation expertise of the other partners.
F2G Ltd. Appoints Ian Nicholson as Director and Chief Executive Officer
Mar 11 13
F2G Ltd. announced the appointment of Ian Nicholson to the position of CEO and to the Board of Directors. Ian is currently, and will remain, an Operating Partner of London-based Advent Life Sciences LLP.
F2G Ltd. Appoints John H. Rex to Board of Directors
Feb 19 13
F2G Ltd. announced the appointment of Dr. John H. Rex to the company’s Board as an Independent Director. He has a BA in Biochemistry from Rice University, an MD from Baylor College of Medicine, and is Vice President and Head of Infection, Global Medicines Development, at AstraZeneca. Dr. Rex, who will continue his role at AstraZeneca.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries